In a $125 million deal, a startup founded by former Seagen CEO Clay Siegall combines with a public business.
[ad_1] Morphimmune, a biotech business founded by former Seagen CEO Clay Siegall, is merging with Immunome, a public biotech company, in a $125 million deal backed by private investors. Siegall will be the CEO, president, and chairman of the board of directors of the merged firm, Immunome, which will be headquartered in Seattle. “This is […]